Table 1.
Clinical and demographic characteristics of study subjects
| Subject group | Age (yr) [median(range)] | Sex (male/female) | CD4 T cell count (cells/μl) [median(range)] | Viral load (copies/ml) [median(range)] | Target epitopes of analyzed CTL populations |
|---|---|---|---|---|---|
| Progressors (n = 11) | 51.5 (39–72) | 9/2 | 458 (331–568) | 139,000 (16,400–402,000) | B8-FL8 (FLKEKGGL, HIV-1 nef) |
| B8-EI8 (EIYKRWII, HIV-1 p24) | |||||
| A2-SL9 (SLYNTVATL, HIV-1 p17) | |||||
| B27-KK10 (KRWIILGLNK, HIV-1 p24) | |||||
| A11-QK10 (QVPLRPMTYK,, HIV-1 nef) | |||||
| A11-KK9 (KIRLRPGGK, HIV-1 p17) | |||||
| B7-IL-9 (IPRRIRQGL, HIV-1 gp41) | |||||
| A2-NV9 (NLVPMVATV, CMV pp65) | |||||
| B8-FL9 (FLRGRAYGL, EBV EBNA-3a) | |||||
| Controllers (n = 13) | 45 (34–64) | 12/1 | 843 (328–1,415) | <50 (<50–1,037) | B8-FL8 (FLKEKGGL, HIV-1 nef) |
| B8-EI8 (EIYKRWII, HIV-1 p24) | |||||
| A2-SL9 (SLYNTVATL, HIV-1 p17) | |||||
| B27-KK10 (KRWIILGLNK, HIV-1 p24) | |||||
| B7-IL-9 (IPRRIRQGL, HIV-1 gp41) | |||||
| B57-KF11 (KAFSPEVIPMF, p24) | |||||
| A2-NV9 (NLVPMVATV, CMV pp65) | |||||
| B8-FL9 (FLRGRAYGL, EBV EBNA-3a) |